US-based antibody therapeutics developer Visterra secured $23.6m yesterday to close a series C round backed by pharmaceutical firm Merck & Co at $46.7m.
The company raised an initial $23.1m in June 2016 from Merck’s investment vehicle MRL Ventures Fund as well as Vertex Ventures, the venture capital arm of Singapore state-owned investment firm Temasek, Polaris Partners, Flagship Ventures and unnamed investors.
The full list of series C backers compiled by Visterra also includes immunobiological drugs manufacturer Serum Institute of…